3.0
May 12, 2022
Recommend
CEO approval
Business Outlook
Pros
Good at making its own compounds; competitive pay package
Cons
Poor at doing studies because most of its marketed drugs relied on external partners (Bayer, Sanofi, etc) to perform the studies with compounds that Regeneron made, so the company is lacking in either expertise or a culture to perform studies itself for its size. Because of the partnership it also makes decisions more complicated since now another company will have a say. Demanding in work hours and pace for industry standards with not much personal touch to treat employees as humans. For the short term it's going to be fine; but it will probably have growing pain soon in the future.